inspirator schreef op 30 oktober 2017 18:08:
GLPG1972 was shown to be safe and well-tolerated in healthy male subjects with a suitable pharmacokinetic profile and a marked decrease of the aggrecan ARGS neoepitope biomarker, indicating target engagement. These data and the preclinical data package confirm the potential of GLPG1972 to be a potential DMOAD treatment. GLPG1972 will be progressed to a Phase 2 study in osteoarthritis.
ABSTRACT NUMBER: 1189
Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the Adamts-5 Inhibitor GLPG1972, a Potential New Treatment in Osteoarthritis
Ellen van der Aar1, Sonia Dupont2, Liesbeth Fagard1, Marina De Smet1, David Amantini2, Staffan Larsson3, André Struglics3, L. Stefan Lohmander4, Frédéric Vanhoutte1 and Julie Desrivot2, 1Galapagos NV, Mechelen, Belgium, 2Galapagos SASU, Romainville, France, 3Clinical Sciences, Lund University, Lund, Sweden, 4Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Meeting: 2017 ACR/ARHP Annual Meeting
Date of first publication: September 18, 2017
Keywords: Osteoarthritis
acrabstracts.org/abstract/favorable-h...